Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease.

Abstract

MTX is an effective second-line treatment of ASD that does not respond to prednisone. It allows significant reduction of corticosteroid doses, which is beneficial to these patients, who have frequent and numerous corticosteroid related adverse events.